Ion channels and the control of blood pressure

British Journal of Clinical Pharmacology

Volumn 49, Issue 3, 2000, Pages 185-198

  Baker, Emma H ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bartter's syndrome; Blood pressure; Epithelium; Ion channels; Liddle's syndrome; Vascular tone

Indexed keywords

8 TERT BUTYL 6,7 DIHYDRO 5 METHYLPYRROLO[3,2 E]PYRAZOLO[1,5 A]PYRIMIDINE 3 CARBONITRILE; AMILORIDE; AMLODIPINE; ANTISENSE OLIGONUCLEOTIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORIDE CHANNEL; CROMAKALIM; CROMOGLYCATE DISODIUM; DILTIAZEM; FUROSEMIDE; GLIBENCLAMIDE; ION CHANNEL; NICORANDIL; NIFEDIPINE; PINACIDIL; POTASSIUM CHANNEL; SODIUM CHANNEL; TRIAMTERENE; VERAPAMIL;

BARTTER SYNDROME; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CHANNEL GATING; EDEMA; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE THERAPY; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; ION TRANSPORT; LIDDLE SYNDROME; MEMBRANE CHANNEL; MEMBRANE CONDUCTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PSEUDOHYPOALDOSTERONISM; REVIEW; SODIUM RESTRICTION; TACHYCARDIA; VASCULAR SMOOTH MUSCLE;

BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; ION CHANNEL GATING; ION CHANNELS; ION TRANSPORT; MUSCLE, SMOOTH; PROTEIN CONFORMATION;

EID: 0034015208     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2000.00159.x     Document Type: Review

References (81)

1. 1 Ackerman MJ, Clapham DE. Ion channels - Basic science and clinical disease. N Engl J Med 1997; 336: 1575-1586.
2. 2 Chaudhuri A, Behan P. Channelopathies in neurological disorders. CNS 1998; 1: 12-15.
3. 3 Schwiebert EM, Benos DJ, Fuller CM. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein. Am J Med 1998; 104: 576-590.
4. + channel by interaction of Nedd4 with a PY motif deleted in Liddle's syndrome. J Biol Chem 1998; 273: 30012-30017.
5. 5 Catterall WA. Structure and function of voltage-gated ion channels. Ann Rev Biochem 1995; 64: 493-531.
6. + channel. Biol Chem 1997; 272: 21075-21083.
7. + channels. Am J Physiol 1995; 268: C535-C556.
8. 8 Hamm-Alvarez SF, Sheetz MP. Microtubule-dependent vesicle transport: modulation of channel and transporter activity in liver and kidney. Physiol Rev 1998; 78: 1109-1129.
9. + channel (ENaC) by ubiquitination. EMBO J 1997; 16: 6325-6336.
10. 10 Shimkets RA, Lifton RP, Canessa CM. The activity of the epithelial sodium channel is mediated by clathrin mediated endocytosis. J Biol Chem 1997; 272: 25537-25541.
11. + channel subunits. Am J Physiol 1996; 271: C605-C611.
12. 12 Kemendy AE, Kleyman TR, Eaton DC. Aldosterone alters the open probability of amiloride-blockable sodium channels in A6 epithelia. Am J Physiol 1992; 263: C825-C837.
13. 13 Garty H, Palmer LG. Epithelial sodium channels: Function, structure and regulation. Physiol Rev 1997; 77: 359-396.
14. 14 Alton EWFW, Kingsleigh-Smith DJ, Munkonge FM, et al. Asthma prophylaxis agents alter the function of an airway epithelial chloride channel. Am J Respir Cell Mol Biol 1996; 14: 380-387.
15. 15 Lafont F, Burkhardt JK, Simons K. Involvement of microtubule motors in basolateral and apical transport in kidney cells. Nature 1994; 372: 801-803.
16. 16 Canessa CM, Horisberger JD, Rossier BC. Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 1993; 361: 467-470.
17. + channel is made up of three homologous subunits. Nature 1994; 367: 463-467.
18. 18 Palmer BF, Alpern RJ. Liddle's syndrome. Am J Med 1998; 104: 301-309.
19. 19 Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Phys 1963; 76: 199-213.
20. 20 Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
21. 21 Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel γ subunit: genetic heterogeneity of Liddle syndrome. Nature Genet 1995; 11: 76-82.
22. + channel. Cell 1995; 83: 969-978.
23. 23 Firsov D, Schild L, Gautschi I, Merillat AM, Schneeberger E, Rossier BC. Cell surface expression of the epithelial sodium channel and a mutant causing Liddle's syndrome: a quantitative approach. PNAS 1996; 93: 15370-15375.
24. 24 Botero-Velez M, Curtis JJ, Warnock DG. Liddle's syndrome revisited - A disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330: 178-181.
25. 25 McDonald FJ, Price MP, Snyder PM, Welsh MJ. Cloning and expression of the beta-and gamma-subunits of the human epithelial sodium channel. Am J Physiol 1995; 268: C1157-1163.
26. 26 Burch LH, Talbot CR, Knowles MR, Canessa CM, Rossier BC, Boucher RC. Relative expression of the human epithelial Na+ channel subunits in normal and cystic fibrosis airways Am. J Physiol 1995; 269: C511-C518.
27. 27 Chinet TC, Fullton JM, Yankaskas JR, Boucher RC, Stutts MJ. Sodium-permeable channels in the apical membrane of human nasal epithelial cells. Am J Physiol 1993; 265: C1050-C1060.
28. 28 Eaton DC, Becchetti A, Ma H, Ling BN. Renal sodium channels: Regulation and single channel properties. Kidney Int 1995; 48: 941-949.
29. 29 Bubien JK, Ismailov IL, Berdiev BK, et al. Liddle's disease: abnormal regulation of amiloride-sensitive Na+ channels by β subunit mutation. Am J Physiol 1996; 270: C208-C213.
30. 30 Baker EH, Jeunemaitre X, Portal AJ, et al. Abnormalities of nasal potential difference measurement in Liddle's Syndrome. J Clin Invest 1998; 102: 10-14.
31. 31 Strautnieks SS, Thompson RJ, Gardiner RM, Chung E. A novel splice-site mutation in the γ subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nature Genet 1996; 13: 248-250.
32. 32 Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nature Genet 1996; 12: 248-253.
33. 33 Persu A, Barbry P, Bassilana F, et al. Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension 1998; 32: 129-137.
34. 34 Melander O, Orho M, Fagerudd J, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension 1998; 31: 1118-1124.
35. 35 Baker EH, Dong YB, Sagnella GA, et al. Association of hypertension with T594M mutation in β subunit of epithelial sodium channels in black people resident in London. Lancet 1998; 351: 1388-1392.
36. 36 Su YR, Rutkowski MP, Klanke CA, et al. A novel variant of the β-subunit of the amiloride-sensitive sodium channel in African Americans. J Am Soc Nephrol 1996; 7: 2543-2549.
37. 37 Shimkets RA, Lifton R, Canessa CM. In vivo phosphorylation of the epithelial sodium channel. Proc Natl Acad Sci USA 1998; 95: 3301-3305.
38. + channel. Proc Natl Acad Sci U S A 1997; 94: 9962-9966.
39. 39 Greger R. Ion transport mechanisms in thick ascending limb of Henle's loop of mammalian nephron. Physiol Rev 1985; 65: 760-797.
40. - absorption. J Gen Physiol 1986; 87: 567-590.
41. + channel, RomK. Nat Genet 1996; 14: 152-156.
42. 42 Schwalbe RA, Bianchi L, Accili EA, Brown AM. Functional consequences of RomK mutants linked to antenatal Bartter's syndrome and implications for treatment. Hum Mol Genet 1998; 7: 975-980.
43. 43 Guay-Woodford LM. Bartter Syndrome: Unravelling the pathophysiologic enigma. Am J Med 1998; 105: 151-161.
44. 44 McNicholas CM, Guggino WB, Schwiebert EM, Hebert SC, Giebisch G, Egan ME. Sensitivity of a renal K+ channel (ROMK2) to the inhibitory sulfonylurea compound glibenclamide is enhanced by coexpression with the ATP-binding cassette transporter cyctic fibrosis transmembrane regulator. Proc Natl Acad Sci USA 1996; 93: 8083-8088.
45. 45 Bailey MA, Walter SJ. Renal effects of glibenclamide: a micropuncture study. J Pharmacol Exp Ther 1998; 285: 464-467.
46. 46 Rado JP, Borbely L, Szende L, Fischer J, Tako J. Investigation of the diuretic effect of glibenclamide in healthy subjects and in patients with pituitary and nephrogenic diabetes insipidus. Horm Metab Res 1974; 6: 289-292.
47. 47 Williams S, Abbott D, Morfis L, Manwaring P, Diamond T, Howes LG. Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. J Hypertens 1998; 16: 705-711.
48. 48 Lieberman J, Rodbard S. Low blood pressure in young adults with cystic fibrosis: an effect of chronic salt loss in sweat? Ann Intern Med 1975; 82: 806-808.
49. 49 Quinton PM. Missing Cl conductance in cystic fibrosis. Am J Physiol 1986; 251: C649-C652.
50. 50 Schweibert EM, Lopes AG, Guggino WB. Chloride channels along the nephron. In Chloride Channels, ed Guggino WB. San Diego: Academic Press, 1994: 265-315.
51. 51 Nilius B, Viana F, Droogmans G. Ion channels in vascular endothelium. Annu Rev Physiol 1997; 59: 145-170.
52. 2+ -permeable cation channel in intact vascular endothelium of hypertensive rats. Prof Natl Acad Sci USA 1996; 93: 11253-11258.
53. 53 Inazu M, Zhang H, Daniel EE. LP-805, a releaser of endothelium-derived nitric oxide, activates an endothelial calcium permeable non-specific cation channel. Life Sci 1993; 53: 315-320.
54. 54 Adams DJ, Barakeh J, Laskey R, Van Breeman C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J 1989; 3: 2389-2400.
55. 2+ concentrations. J Gen Physiol 1996; 107: 459-472.
56. 56 Clapp LH, Tinker A. Potassium channels in the vasculature. Curr Opin Nephrol Hypertens 1998; 7: 91-98.
57. 57 Orallo F. Regulation of cytosolic calcium levels in vascular smooth muscle. Pharmacol Ther 1996; 69: 153-171.
58. 2+ channels in arterial smooth muscle cells. Kidney Blood Press Res 1997; 20: 355-371.
59. 59 Martens JR, Gelband CH. Ion channels in vascular smooth muscle: alterations in essential hypertension. Proc Soc Exp Biol Med 1998; 218: 192-203.
60. + current is enhanced in arterial membranes of hypertensive rats. Hypertension 1992; 19: 301-307.
61. + current in arterial membranes from genetically hypertensive rats. Am J Physiol 1993; 264: H1337-H1345.
62. + channels in mesenteric artery cells from spontaneously hypertensive rats. Hypertension 1996; 27: 1234-1239.
63. 63 Rusch NJ, Runnells AM. Remission of high blood pressure reverses arterial potassium channel alterations. Hypertension 1994; 23: 941-945.
64. 64 Benham CD, Tsien RW. Calcium-permeable channels in vascular smooth muscle: Voltage-activated, receptor operated, and leak channels. Soc Gen Physiol Ser 1987; 42: 45-64.
65. 65 Glasser SP. The relevance of T-type calcium antagonists: a profile of mibefradil. J Clin Pharmacol 1998; 38: 659-669.
66. 66 Schmitt R, Clozel J-P, Iberg N, Buhler FR. Mibefradil prevents neointima formation after vascular injury in rats. Arterioscler Thromb Vasc Biol 1995; 15: 1161-1165.
67. 67 Mishra SK, Hermsmeyer K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ Res 1994; 75: 144-148.
68. 68 Oparil S. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension. Am J Hypertens 1998; 11: 88S-94S.
69. 69 Po AL, Zhang WY. What lessons can be learnt from withdrawal of mibefradil from the market? Lancet 1998; 351: 1829-1830.
70. 70 Giles TD. Hypertension and pathologic cardiovascular remodeling: a potential therapeutic role for T-type calcium antagonists. Clin Ther 1997; 19(Suppl A): 27-38.
71. 71 Edwards G, Weston AH. Pharmacology of the potassium channel openers. Cardiovasc Drugs Ther 1995; 9: 185-193.
72. 72 Webb DJ, Benjamin N, Vallance P. The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers. Br J Clin Pharmacol 1989; 27: 757-761.
73. 73 Carlsen JE, Kardel T, Lund JO, McNair A, Trap-Jensen J. Acute haemodynamic effects of pinacidil and hydralazine in essential hypertension. Clin Pharmacol Ther 1985; 37: 253-259.
74. 74 Singer DR, Markandu ND, Miller MA, Sugden AL, MacGregor GA. Potassium channel stimulation in normal subjects and in patients with essential hypertension: an acute study with cromakalim (BRL 34915). J Hypertens 1989; 7: S294-S295.
75. 75 Carlsen JE, Jensen HA, Rehling M, Lund JO, Trap-Jensen J. Long-term haemodynamic effects of pinacidil and hydralazine in arterial hypertension. Drugs 1988; 36(Suppl 7): 55-63.
76. 76 Goldberg MR. Clinical pharmacology of pinacidil. A prototype for drugs that affect potassium channels. J Cardiovasc Pharmacol 1988; 12(Suppl 2): 41-47.
77. 77 Goldschmidt M, Landzberg BR, Frishman WH. Nicorandil: a potassium channel opening drug for treatment of ischemic heart disease. J Clin Pharmacol 1996; 36: 559-572.
78. + channel mediates hypotension in endotoxaemia and hypoxic lactic acidosis in dog. J Clin Invest 1992; 89: 2071-2074.
79. 79 Vanelli G, Hussain SNA, Aguggini G. Glibenclamide, a blocker of ATP-sensitive potassium channels, reverses endotoxin-induced hypotension in pig. Exp Physiol 1995; 80: 167-170.
80. 80 Szabo C, Salzman AL. Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe haemorrhagic shock. Shock 1996; 5: 391-394.
81. ATP-channel inhibition improves hemodynamics and cellular energetics in hemorrhagic shock. Am J Physiol 1997; 41: H688-H694.